Study of PARP1 inhibitor EIK1004 for advanced solid tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced cancer such as breast, ovarian, prostate, or pancreatic cancer that has spread or come back after treatment.
- You have a harmful change (mutation) in a gene that helps repair DNA (like BRCA1 or BRCA2) – this can be found in your tumor or blood.
- You have had at least one prior chemotherapy or targeted therapy for your cancer, depending on the type.
- You have not had more than one PARP inhibitor (like Lynparza, Zejula, or Rubraca) in the past.
- You are generally well enough to do daily activities (ECOG performance status 0 or 1) and have adequate organ function.
- You are willing to use effective birth control during the study and for 6 months after the last dose of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This trial tests if niraparib, a targeted therapy pill, can shrink advanced solid cancers that have specific DNA repair flaws (HRD). It's for people whose tumors have certain gene mutations or DNA damage signatures.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.